Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects
Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig). Methods. This phase I trial evaluated an HIV-...
Saved in:
| Published in | The Journal of infectious diseases Vol. 204; no. 10; pp. 1541 - 1549 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Oxford University Press
15.11.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-1899 1537-6613 1537-6613 |
| DOI | 10.1093/infdis/jir615 |
Cover
| Abstract | Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig). Methods. This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects received placebo (group C), adjuvant alone (group A), vaccine alone (group D), increasing doses of adjuvant concurrent with vaccine (groups T1-T4), or adjuvant given 2 days after vaccine (group T5). Results. No significant differences in adverse events were observed between treatment groups. Cellular immune responses to envelope protein EnvA peptides were detected by interferon (IFN) γ and IL-2 enzymelinked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively, in T4, and in 100% and 80% in T5. The median responses for groups T4 and T5, respectively, were 90 and 193 spot-forming cells (SFCs)/10⁶ peripheral blood mononuclear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/10⁶ PBMCs (P = .003; T4 vs T5) for the IFN-γ ELISPOT assay. A trend to more durable cellular immune responses in T5 was observed at 1 year (T5 vs T4/D; P = .07). Higher anti-Env antibody responses were detected with T5 than with T4. Conclusions. Plasmid IL-2/Ig significantly increased immune responses when administered 2 days after the DNA vaccine, compared with simultaneous administration. These observations have important implications for the development of cytokine augmentation strategies. |
|---|---|
| AbstractList | Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig). Methods. This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects received placebo (group C), adjuvant alone (group A), vaccine alone (group D), increasing doses of adjuvant concurrent with vaccine (groups T1-T4), or adjuvant given 2 days after vaccine (group T5). Results. No significant differences in adverse events were observed between treatment groups. Cellular immune responses to envelope protein EnvA peptides were detected by interferon (IFN) γ and IL-2 enzymelinked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively, in T4, and in 100% and 80% in T5. The median responses for groups T4 and T5, respectively, were 90 and 193 spot-forming cells (SFCs)/10⁶ peripheral blood mononuclear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/10⁶ PBMCs (P = .003; T4 vs T5) for the IFN-γ ELISPOT assay. A trend to more durable cellular immune responses in T5 was observed at 1 year (T5 vs T4/D; P = .07). Higher anti-Env antibody responses were detected with T5 than with T4. Conclusions. Plasmid IL-2/Ig significantly increased immune responses when administered 2 days after the DNA vaccine, compared with simultaneous administration. These observations have important implications for the development of cytokine augmentation strategies. Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig). Methods. This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects received placebo (group C), adjuvant alone (group A), vaccine alone (group D), increasing doses of adjuvant concurrent with vaccine (groups T1-T4), or adjuvant given 2 days after vaccine (group T5). Results. No significant differences in adverse events were observed between treatment groups. Cellular immune responses to envelope protein EnvA peptides were detected by interferon (IFN) γ and IL-2 enzyme-linked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively, in T4, and in 100% and 80% in T5. The median responses for groups T4 and T5, respectively, were 90 and 193 spot-forming cells (SFCs)/106 peripheral blood mononuclear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/106 PBMCs (P = .003; T4 vs T5) for the IFN-γ ELISPOT assay. A trend to more durable cellular immune responses in T5 was observed at 1 year (T5 vs T4/D; P = .07). Higher anti-Env antibody responses were detected with T5 than with T4. Conclusions. Plasmid IL-2/Ig significantly increased immune responses when administered 2 days after the DNA vaccine, compared with simultaneous administration. These observations have important implications for the development of cytokine augmentation strategies. Clinical Trials Registration. NCT00069030. Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig). Methods. This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects received placebo (group C), adjuvant alone (group A), vaccine alone (group D), increasing doses of adjuvant concurrent with vaccine (groups T1-T4), or adjuvant given 2 days after vaccine (group T5). Results. No significant differences in adverse events were observed between treatment groups. Cellular immune responses to envelope protein EnvA peptides were detected by interferon (IFN) gamma and IL-2 enzymelinked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively, in T4, and in 100% and 80% in T5. The median responses for groups T4 and T5, respectively, were 90 and 193 spot-forming cells (SFCs)/10 super(6) peripheral blood mononuclear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/10 super(6) PBMCs (P = .003; T4 vs T5) for the IFN-c ELISPOT assay. A trend to more durable cellular immune responses in T5 was observed at 1 year (T5 vs T4/D; P = .07). Higher anti-Env antibody responses were detected with T5 than with T4. Conclusions. Plasmid IL-2/Ig significantly increased immune responses when administered 2 days after the DNA vaccine, compared with simultaneous administration. These observations have important implications for the development of cytokine augmentation strategies. Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig). Methods. This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects received placebo (group C), adjuvant alone (group A), vaccine alone (group D), increasing doses of adjuvant concurrent with vaccine (groups T1–T4), or adjuvant given 2 days after vaccine (group T5). Results. No significant differences in adverse events were observed between treatment groups. Cellular immune responses to envelope protein EnvA peptides were detected by interferon (IFN) γ and IL-2 enzyme-linked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively, in T4, and in 100% and 80% in T5. The median responses for groups T4 and T5, respectively, were 90 and 193 spot-forming cells (SFCs)/106 peripheral blood mononuclear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/106 PBMCs (P = .003; T4 vs T5) for the IFN-γ ELISPOT assay. A trend to more durable cellular immune responses in T5 was observed at 1 year (T5 vs T4/D; P = .07). Higher anti-Env antibody responses were detected with T5 than with T4. Conclusions. Plasmid IL-2/Ig significantly increased immune responses when administered 2 days after the DNA vaccine, compared with simultaneous administration. These observations have important implications for the development of cytokine augmentation strategies. Clinical Trials Registration. NCT00069030. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig).BACKGROUNDTo investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig).This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects received placebo (group C), adjuvant alone (group A), vaccine alone (group D), increasing doses of adjuvant concurrent with vaccine (groups T1-T4), or adjuvant given 2 days after vaccine (group T5).METHODSThis phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects received placebo (group C), adjuvant alone (group A), vaccine alone (group D), increasing doses of adjuvant concurrent with vaccine (groups T1-T4), or adjuvant given 2 days after vaccine (group T5).No significant differences in adverse events were observed between treatment groups. Cellular immune responses to envelope protein EnvA peptides were detected by interferon (IFN) γ and IL-2 enzyme-linked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively, in T4, and in 100% and 80% in T5. The median responses for groups T4 and T5, respectively, were 90 and 193 spot-forming cells (SFCs)/10⁶ peripheral blood mononuclear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/10⁶ PBMCs (P = .003; T4 vs T5) for the IFN-γ ELISPOT assay. A trend to more durable cellular immune responses in T5 was observed at 1 year (T5 vs T4/D; P = .07). Higher anti-Env antibody responses were detected with T5 than with T4.RESULTSNo significant differences in adverse events were observed between treatment groups. Cellular immune responses to envelope protein EnvA peptides were detected by interferon (IFN) γ and IL-2 enzyme-linked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively, in T4, and in 100% and 80% in T5. The median responses for groups T4 and T5, respectively, were 90 and 193 spot-forming cells (SFCs)/10⁶ peripheral blood mononuclear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/10⁶ PBMCs (P = .003; T4 vs T5) for the IFN-γ ELISPOT assay. A trend to more durable cellular immune responses in T5 was observed at 1 year (T5 vs T4/D; P = .07). Higher anti-Env antibody responses were detected with T5 than with T4.Plasmid IL-2/Ig significantly increased immune responses when administered 2 days after the DNA vaccine, compared with simultaneous administration. These observations have important implications for the development of cytokine augmentation strategies.CONCLUSIONSPlasmid IL-2/Ig significantly increased immune responses when administered 2 days after the DNA vaccine, compared with simultaneous administration. These observations have important implications for the development of cytokine augmentation strategies.NCT00069030.CLINICAL TRIALS REGISTRATIONNCT00069030. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig). This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects received placebo (group C), adjuvant alone (group A), vaccine alone (group D), increasing doses of adjuvant concurrent with vaccine (groups T1-T4), or adjuvant given 2 days after vaccine (group T5). No significant differences in adverse events were observed between treatment groups. Cellular immune responses to envelope protein EnvA peptides were detected by interferon (IFN) γ and IL-2 enzyme-linked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively, in T4, and in 100% and 80% in T5. The median responses for groups T4 and T5, respectively, were 90 and 193 spot-forming cells (SFCs)/10⁶ peripheral blood mononuclear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/10⁶ PBMCs (P = .003; T4 vs T5) for the IFN-γ ELISPOT assay. A trend to more durable cellular immune responses in T5 was observed at 1 year (T5 vs T4/D; P = .07). Higher anti-Env antibody responses were detected with T5 than with T4. Plasmid IL-2/Ig significantly increased immune responses when administered 2 days after the DNA vaccine, compared with simultaneous administration. These observations have important implications for the development of cytokine augmentation strategies. NCT00069030. |
| Author | Brandariz, Kara Sobieszczyk, Magdalena E. Barouch, Dan H. Cardinali, Massimo Dolin, Raphael Blattner, William A. Tomaras, Georgia D. Baden, Lindsey R. Kochar, Nidhi Huang, Yunda Graham, Barney S. Russell, Nina McElrath, M. Juliana Morgan, Cecilia Defawe, Olivier D. |
| AuthorAffiliation | 6 Vaccine and Infectious Disease Division 10 Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 3 Department of Medicine, Institute of Human Virology Epidemiology Division, University of Maryland, Baltimore 9 Division of Infectious Diseases, College of Physicians and Surgeons & Columbia University Medical Center, New York 7 Statistical Center for HIV/AIDS Research & Prevention (SCHARP), Fred Hutchinson Cancer Research Center 8 Bill & Melinda Gates Foundation, Global Health Program, Seattle, Washington 1 Department of Medicine, Brigham and Women’s Hospital 5 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 4 Division of AIDS 2 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts |
| AuthorAffiliation_xml | – name: 2 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts – name: 3 Department of Medicine, Institute of Human Virology Epidemiology Division, University of Maryland, Baltimore – name: 5 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland – name: 6 Vaccine and Infectious Disease Division – name: 9 Division of Infectious Diseases, College of Physicians and Surgeons & Columbia University Medical Center, New York – name: 10 Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina – name: 1 Department of Medicine, Brigham and Women’s Hospital – name: 7 Statistical Center for HIV/AIDS Research & Prevention (SCHARP), Fred Hutchinson Cancer Research Center – name: 4 Division of AIDS – name: 8 Bill & Melinda Gates Foundation, Global Health Program, Seattle, Washington |
| Author_xml | – sequence: 1 givenname: Lindsey R. surname: Baden fullname: Baden, Lindsey R. – sequence: 2 givenname: William A. surname: Blattner fullname: Blattner, William A. – sequence: 3 givenname: Cecilia surname: Morgan fullname: Morgan, Cecilia – sequence: 4 givenname: Yunda surname: Huang fullname: Huang, Yunda – sequence: 5 givenname: Olivier D. surname: Defawe fullname: Defawe, Olivier D. – sequence: 6 givenname: Magdalena E. surname: Sobieszczyk fullname: Sobieszczyk, Magdalena E. – sequence: 7 givenname: Nidhi surname: Kochar fullname: Kochar, Nidhi – sequence: 8 givenname: Georgia D. surname: Tomaras fullname: Tomaras, Georgia D. – sequence: 9 givenname: M. Juliana surname: McElrath fullname: McElrath, M. Juliana – sequence: 10 givenname: Nina surname: Russell fullname: Russell, Nina – sequence: 11 givenname: Kara surname: Brandariz fullname: Brandariz, Kara – sequence: 12 givenname: Massimo surname: Cardinali fullname: Cardinali, Massimo – sequence: 13 givenname: Barney S. surname: Graham fullname: Graham, Barney S. – sequence: 14 givenname: Dan H. surname: Barouch fullname: Barouch, Dan H. – sequence: 15 givenname: Raphael surname: Dolin fullname: Dolin, Raphael |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24819544$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21940420$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks1v0zAYxi00xLrBkSPIF8Q4ZPVH7DgXpKraWKRKIG3sarmOXVwSu8TJUP973KaUDwl28sG_5_XzPK_PwIkP3gDwEqNLjEo6dd7WLk7XruOYPQETzGiRcY7pCZggREiGRVmegrMY1wihnPLiGTgluMxRTtAEDHeudX4Fg4WfGhVbV8P5tg9fnTfwolpkZFqt3sFZnSAX-071Lng4s9boPsKb6j7D8F5pvcOrth18WBnvtOu30Pn9_a3pkuFVEj4YeDss1zvlc_DUqiaaF4fzHHy-vrqb32SLjx-q-WyRaYbyPrOsTqEQYrURwnLKk_1SMYTtUgllLNOC1YrgAi2NFoRZrlWBmKhrKhjlip6Dy3Hu4Ddq-101jdx0rlXdVmIkd_3JsT859pcE70fBZli2ptbGp8y_REE5-eeNd1_kKjxISgjBSKQBbw8DuvBtMLGXrYvaNI3yJgxRlohxXog9efFfEnOWc8EwLRL6-ndXRzs_15iANwdARa0a2ymvU6gjlwtcsjxPXDZyugsxdsY-Wgf9i0-r3f-BFN41_1QdkoVh8-gDr0Z0HfvQHeEcU1IKxOgPo8voWw |
| CODEN | JIDIAQ |
| CitedBy_id | crossref_primary_10_3390_vaccines7020038 crossref_primary_10_1016_j_it_2018_11_003 crossref_primary_10_1128_microbiolspec_PLAS_0028_2014 crossref_primary_10_1080_13543784_2020_1724281 crossref_primary_10_1016_j_cytogfr_2012_05_006 crossref_primary_10_1089_aid_2015_0101 crossref_primary_10_1111_j_1365_2567_2011_03517_x crossref_primary_10_1093_infdis_jis670 crossref_primary_10_1093_infdis_jit236 crossref_primary_10_1016_j_vaccine_2015_03_036 crossref_primary_10_1038_ncomms6317 crossref_primary_10_1111_imr_13234 crossref_primary_10_1016_j_vaccine_2019_04_055 crossref_primary_10_1016_j_vaccine_2013_06_011 crossref_primary_10_1177_2051013613494535 crossref_primary_10_3390_vaccines2010160 |
| Cites_doi | 10.1038/nm.2089 10.1056/NEJM199803263381301 10.1086/509258 10.1056/NEJM199804303381805 10.1126/science.280.5371.1875 10.1016/S0140-6736(08)61591-3 10.1016/j.vaccine.2004.01.065 10.4049/jimmunol.161.4.1875 10.1016/j.vaccine.2007.02.050 10.1056/NEJM199710303371803 10.1073/pnas.90.9.4156 10.1016/j.virol.2006.04.043 10.1016/j.vaccine.2006.07.050 10.1056/NEJMoa0908492 10.1126/science.278.5342.1447 10.1002/cyto.a.20600 10.1097/CJI.0b013e31802ff843 10.1093/annonc/mdm331 10.1016/j.jim.2006.07.015 10.1016/S0264-410X(96)00251-4 10.1097/QAI.0b013e3180377b5b 10.1086/509259 10.1128/JVI.01708-08 10.1056/NEJM199610313351803 10.1126/science.290.5491.486 10.4049/jimmunol.158.10.4591 10.1084/jem.189.6.991 10.1073/pnas.050417697 10.1097/QAI.0b013e3180417cb6 10.1089/aid.2007.0047 10.1097/01.qai.0000248356.48501.ff 10.1126/science.279.5359.2103 10.1007/s00262-010-0875-4 10.1126/science.283.5403.857 10.1016/j.vaccine.2006.06.009 10.1016/j.jim.2007.03.002 10.2307/2533072 10.1016/j.vaccine.2007.08.056 10.1016/S0140-6736(08)61592-5 10.1056/NEJMoa0903175 |
| ContentType | Journal Article |
| Copyright | Copyright © 2011 Oxford University Press The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2011 2015 INIST-CNRS |
| Copyright_xml | – notice: Copyright © 2011 Oxford University Press – notice: The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2011 – notice: 2015 INIST-CNRS |
| CorporateAuthor | the NIAID HIV Vaccine Trials Network 044 Study Team NIAID HIV Vaccine Trials Network 044 Study Team |
| CorporateAuthor_xml | – name: the NIAID HIV Vaccine Trials Network 044 Study Team – name: NIAID HIV Vaccine Trials Network 044 Study Team |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 5PM ADTOC UNPAY |
| DOI | 10.1093/infdis/jir615 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1537-6613 |
| EndPage | 1549 |
| ExternalDocumentID | 10.1093/infdis/jir615 PMC3222108 21940420 24819544 10_1093_infdis_jir615 41329805 |
| Genre | Multicenter Study Clinical Trial, Phase I Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: P30 AI060354 – fundername: NIAID NIH HHS grantid: U01 AI068618 |
| GroupedDBID | --- -DZ -~X ..I .2P .I3 .XZ .ZR 08P 0R~ 123 1KJ 1TH 29K 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWTL ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACGOD ACHIC ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TR2 W2D W8F WH7 X7H YAYTL YKOAZ YXANX ~91 AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 AAYXX CITATION .55 .GJ 3O- 41~ AAFWJ AAPGJ AAWDT ABDPE ABSMQ ACFRR ACPQN ACUTJ ACVCV ACZBC ADMTO AEKPW AFFQV AFHKK AFQQW AFSHK AGKRT AGMDO AHGBF AI. AJDVS APJGH AQDSO AQKUS AVNTJ BZKNY EIHJH HQ3 HTVGU IQODW J5H MBLQV MVM N4W NEJ OBFPC O~Y P0- TMA VH1 X7M Y6R ZE2 ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c504t-f5d615005de88f6364369a501fba8aef5c85da2170bec825f6ca7058dd38536a3 |
| IEDL.DBID | UNPAY |
| ISSN | 0022-1899 1537-6613 |
| IngestDate | Tue Aug 19 16:44:59 EDT 2025 Tue Sep 30 17:16:24 EDT 2025 Sun Sep 28 00:35:16 EDT 2025 Wed Oct 01 12:23:45 EDT 2025 Mon Jul 21 05:59:34 EDT 2025 Mon Jul 21 09:14:11 EDT 2025 Thu Apr 24 23:08:42 EDT 2025 Wed Oct 01 03:31:03 EDT 2025 Wed Sep 11 05:00:25 EDT 2024 Fri Jun 20 02:31:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Immunoglobulins HIV-1 virus Cytokine Retroviridae Vaccine Lentivirus HIV-2 virus Virus Infection Plasmid Immunogenicity Interleukin 2 Human immunodeficiency virus |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c504t-f5d615005de88f6364369a501fba8aef5c85da2170bec825f6ca7058dd38536a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Presented in part: AIDS Vaccine 2007 meeting, Seattle, Washington, 20–23 August 2007. |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://academic.oup.com/jid/article-pdf/204/10/1541/18065397/jir615.pdf |
| PMID | 21940420 |
| PQID | 1654685137 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | unpaywall_primary_10_1093_infdis_jir615 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3222108 proquest_miscellaneous_905667808 proquest_miscellaneous_1654685137 pubmed_primary_21940420 pascalfrancis_primary_24819544 crossref_primary_10_1093_infdis_jir615 crossref_citationtrail_10_1093_infdis_jir615 oup_primary_10_1093_infdis_jir615 jstor_primary_41329805 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-11-15 |
| PublicationDateYYYYMMDD | 2011-11-15 |
| PublicationDate_xml | – month: 11 year: 2011 text: 2011-11-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: United States |
| PublicationTitle | The Journal of infectious diseases |
| PublicationTitleAlternate | J Infect Dis |
| PublicationYear | 2011 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Musey ( key 20180328153448_bib9) 1997; 337 Catanzaro ( key 20180328153448_bib35) 2006; 194 Barouch ( key 20180328153448_bib13) 2000; 290 Eller ( key 20180328153448_bib15) 2007; 25 Wang ( key 20180328153448_bib17) 1993; 90 Shulman ( key 20180328153448_bib29) 2008; 73 Iwasaki ( key 20180328153448_bib20) 1997; 158 Barouch ( key 20180328153448_bib42) 2004; 22 Recchia ( key 20180328153448_bib22) 2007; 30 Liao ( key 20180328153448_bib32) 2006; 353 Letvin ( key 20180328153448_bib2) 1998; 280 Buchbinder ( key 20180328153448_bib6) 2008; 372 Jin ( key 20180328153448_bib12) 1999; 189 Schmitz ( key 20180328153448_bib11) 1999; 283 Tavel ( key 20180328153448_bib19) 2007; 44 Li ( key 20180328153448_bib30) 2006; 24 Barouch ( key 20180328153448_bib24) 1998; 161 Goepfert ( key 20180328153448_bib4) 2007; 25 Ogg ( key 20180328153448_bib10) 1998; 279 Barouch ( key 20180328153448_bib38) 2010; 16 Negrier ( key 20180328153448_bib40) 1998; 338 Kovacs ( key 20180328153448_bib41) 1996; 335 Moodie ( key 20180328153448_bib27) 2006; 315 Middleton ( key 20180328153448_bib23) 2007; 18 Dubey ( key 20180328153448_bib26) 2007; 45 Goujard ( key 20180328153448_bib21) 2007; 23 Agresti ( key 20180328153448_bib34) 1996; 52 Shiver ( key 20180328153448_bib18) 1997; 15 Baden ( key 20180328153448_bib36) 2009 Rosenberg ( key 20180328153448_bib14) 1997; 278 Russell ( key 20180328153448_bib5) 2007; 44 Tomaras ( key 20180328153448_bib31) 2008; 82 Abrams ( key 20180328153448_bib39) 2009; 361 Rerks-Ngarm ( key 20180328153448_bib8) 2009; 361 Horton ( key 20180328153448_bib28) 2007; 323 Palella ( key 20180328153448_bib1) 1998; 338 McElrath ( key 20180328153448_bib7) 2008; 372 Catanzaro ( key 20180328153448_bib16) 2007; 25 Barouch ( key 20180328153448_bib25) 2000; 97 Moodie ( key 20180328153448_bib33) 2010; 59 Graham ( key 20180328153448_bib3) 2006; 194 Parker ( key 20180328153448_bib37) 2010 17106277 - J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12 17310936 - J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7 16959262 - J Immunol Methods. 2006 Aug 31;315(1-2):121-32 19828532 - N Engl J Med. 2009 Oct 15;361(16):1548-59 9367954 - Science. 1997 Nov 21;278(5342):1447-50 17457219 - J Immunother. 2007 May-Jun;30(4):448-54 17451739 - J Immunol Methods. 2007 May 31;323(1):39-54 11039923 - Science. 2000 Oct 20;290(5491):486-92 9562581 - N Engl J Med. 1998 Apr 30;338(18):1272-8 17391815 - Vaccine. 2007 May 16;25(20):4085-92 17039602 - Virology. 2006 Sep 30;353(2):268-82 17919105 - AIDS Res Hum Retroviruses. 2007 Sep;23(9):1105-13 9516110 - Science. 1998 Mar 27;279(5359):2103-6 16890329 - Vaccine. 2006 Nov 17;24(47-48):6893-904 19012957 - Lancet. 2008 Nov 29;372(9653):1894-905 17920731 - Vaccine. 2007 Nov 7;25(45):7737-42 10759543 - Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4192-7 9712056 - J Immunol. 1998 Aug 15;161(4):1875-82 17325604 - J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):601-5 20549207 - Cancer Immunol Immunother. 2010 Oct;59(10):1489-501 19012954 - Lancet. 2008 Nov 29;372(9653):1881-93 9933172 - Science. 1999 Feb 5;283(5403):857-60 20173752 - Nat Med. 2010 Mar;16(3):319-23 17709802 - Ann Oncol. 2007 Oct;18(10):1691-7 8857018 - N Engl J Med. 1996 Oct 31;335(18):1350-6 8483929 - Proc Natl Acad Sci U S A. 1993 May 1;90(9):4156-60 8805770 - Biometrics. 1996 Sep;52(3):1103-11 17049679 - Vaccine. 2007 Jan 5;25(3):510-8 9345075 - N Engl J Med. 1997 Oct 30;337(18):1267-74 19843557 - N Engl J Med. 2009 Dec 3;361(23):2209-20 17109336 - J Infect Dis. 2006 Dec 15;194(12):1650-60 9234539 - Vaccine. 1997 Jun;15(8):884-7 18842730 - J Virol. 2008 Dec;82(24):12449-63 9632379 - Science. 1998 Jun 19;280(5371):1875-80 15297060 - Vaccine. 2004 Aug 13;22(23-24):3092-7 10075982 - J Exp Med. 1999 Mar 15;189(6):991-8 9516219 - N Engl J Med. 1998 Mar 26;338(13):853-60 17109335 - J Infect Dis. 2006 Dec 15;194(12):1638-49 18615598 - Cytometry A. 2008 Sep;73(9):847-56 9144471 - J Immunol. 1997 May 15;158(10):4591-601 |
| References_xml | – volume: 16 start-page: 319 year: 2010 ident: key 20180328153448_bib38 article-title: Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys publication-title: Nat Med doi: 10.1038/nm.2089 – volume: 338 start-page: 853 year: 1998 ident: key 20180328153448_bib1 article-title: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators publication-title: N Engl J Med doi: 10.1056/NEJM199803263381301 – volume: 194 start-page: 1638 year: 2006 ident: key 20180328153448_bib35 article-title: Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector publication-title: J Infect Dis doi: 10.1086/509258 – volume: 338 start-page: 1272 year: 1998 ident: key 20180328153448_bib40 article-title: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie publication-title: N Engl J Med doi: 10.1056/NEJM199804303381805 – volume: 280 start-page: 1875 year: 1998 ident: key 20180328153448_bib2 article-title: Progress in the development of an HIV-1 vaccine publication-title: Science doi: 10.1126/science.280.5371.1875 – volume: 372 start-page: 1881 year: 2008 ident: key 20180328153448_bib6 article-title: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial publication-title: Lancet doi: 10.1016/S0140-6736(08)61591-3 – volume: 22 start-page: 3092 year: 2004 ident: key 20180328153448_bib42 article-title: Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant publication-title: Vaccine doi: 10.1016/j.vaccine.2004.01.065 – volume: 161 start-page: 1875 year: 1998 ident: key 20180328153448_bib24 article-title: Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration publication-title: J Immunol doi: 10.4049/jimmunol.161.4.1875 – volume: 25 start-page: 4085 year: 2007 ident: key 20180328153448_bib16 article-title: Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2007.02.050 – volume: 337 start-page: 1267 year: 1997 ident: key 20180328153448_bib9 article-title: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection publication-title: N Engl J Med doi: 10.1056/NEJM199710303371803 – volume: 90 start-page: 4156 year: 1993 ident: key 20180328153448_bib17 article-title: Gene inoculation generates immune responses against human immunodeficiency virus type 1 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.90.9.4156 – year: 2010 ident: key 20180328153448_bib37 article-title: Phase I trial of a prophylactic HIV-1 gag-pol-env DNA plasmid vaccine with IL-12 or IL-15 DNA molecular adjuvants (HVTN 070) publication-title: AIDS Vaccine Meet – volume: 353 start-page: 268 year: 2006 ident: key 20180328153448_bib32 article-title: A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses publication-title: Virology doi: 10.1016/j.virol.2006.04.043 – volume: 25 start-page: 510 year: 2007 ident: key 20180328153448_bib4 article-title: Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers publication-title: Vaccine doi: 10.1016/j.vaccine.2006.07.050 – volume: 361 start-page: 2209 year: 2009 ident: key 20180328153448_bib8 article-title: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand publication-title: N Engl J Med doi: 10.1056/NEJMoa0908492 – volume: 278 start-page: 1447 year: 1997 ident: key 20180328153448_bib14 article-title: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia publication-title: Science doi: 10.1126/science.278.5342.1447 – volume: 73 start-page: 847 year: 2008 ident: key 20180328153448_bib29 article-title: Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials publication-title: Cytometry A doi: 10.1002/cyto.a.20600 – volume: 30 start-page: 448 year: 2007 ident: key 20180328153448_bib22 article-title: Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma publication-title: J Immunother doi: 10.1097/CJI.0b013e31802ff843 – volume: 18 start-page: 1691 year: 2007 ident: key 20180328153448_bib23 article-title: Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-α2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma publication-title: Ann Oncol doi: 10.1093/annonc/mdm331 – volume: 315 start-page: 121 year: 2006 ident: key 20180328153448_bib27 article-title: Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials publication-title: J Immunol Methods doi: 10.1016/j.jim.2006.07.015 – volume: 15 start-page: 884 year: 1997 ident: key 20180328153448_bib18 article-title: Anti-HIV env immunities elicited by nucleic acid vaccines publication-title: Vaccine doi: 10.1016/S0264-410X(96)00251-4 – year: 2009 ident: key 20180328153448_bib36 article-title: Phase I trials of a prophylactic HIV-1 gag vaccine with IL-12 or IL-15 DNA molecular adjuvant (HVTN060 and 063) publication-title: AIDS Vaccine Meet – volume: 45 start-page: 20 year: 2007 ident: key 20180328153448_bib26 article-title: Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3180377b5b – volume: 194 start-page: 1650 year: 2006 ident: key 20180328153448_bib3 article-title: Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine publication-title: J Infect Dis doi: 10.1086/509259 – volume: 82 start-page: 12449 year: 2008 ident: key 20180328153448_bib31 article-title: Initial B cell responses to transmitted human immunodeficiency virus type 1: virion binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia publication-title: J Virol doi: 10.1128/JVI.01708-08 – volume: 335 start-page: 1350 year: 1996 ident: key 20180328153448_bib41 article-title: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus publication-title: N Engl J Med doi: 10.1056/NEJM199610313351803 – volume: 290 start-page: 486 year: 2000 ident: key 20180328153448_bib13 article-title: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination publication-title: Science doi: 10.1126/science.290.5491.486 – volume: 158 start-page: 4591 year: 1997 ident: key 20180328153448_bib20 article-title: Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines publication-title: J Immunol doi: 10.4049/jimmunol.158.10.4591 – volume: 189 start-page: 991 year: 1999 ident: key 20180328153448_bib12 article-title: Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques publication-title: J Exp Med doi: 10.1084/jem.189.6.991 – volume: 97 start-page: 4192 year: 2000 ident: key 20180328153448_bib25 article-title: Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.050417697 – volume: 44 start-page: 601 year: 2007 ident: key 20180328153448_bib19 article-title: Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3180417cb6 – volume: 23 start-page: 1105 year: 2007 ident: key 20180328153448_bib21 article-title: Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2007.0047 – volume: 44 start-page: 203 year: 2007 ident: key 20180328153448_bib5 article-title: Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000248356.48501.ff – volume: 279 start-page: 2103 year: 1998 ident: key 20180328153448_bib10 article-title: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA publication-title: Science doi: 10.1126/science.279.5359.2103 – volume: 59 start-page: 1489 year: 2010 ident: key 20180328153448_bib33 article-title: Response definition criteria for ELISPOT assays revisited publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0875-4 – volume: 283 start-page: 857 year: 1999 ident: key 20180328153448_bib11 article-title: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes publication-title: Science doi: 10.1126/science.283.5403.857 – volume: 24 start-page: 6893 year: 2006 ident: key 20180328153448_bib30 article-title: Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation publication-title: Vaccine doi: 10.1016/j.vaccine.2006.06.009 – volume: 323 start-page: 39 year: 2007 ident: key 20180328153448_bib28 article-title: Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination publication-title: J Immunol Methods doi: 10.1016/j.jim.2007.03.002 – volume: 52 start-page: 1103 year: 1996 ident: key 20180328153448_bib34 article-title: Order-restricted tests for stratified comparisons of binomial proportions publication-title: Biometrics doi: 10.2307/2533072 – volume: 25 start-page: 7737 year: 2007 ident: key 20180328153448_bib15 article-title: Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans publication-title: Vaccine doi: 10.1016/j.vaccine.2007.08.056 – volume: 372 start-page: 1894 year: 2008 ident: key 20180328153448_bib7 article-title: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis publication-title: Lancet doi: 10.1016/S0140-6736(08)61592-5 – volume: 361 start-page: 1548 year: 2009 ident: key 20180328153448_bib39 article-title: Interleukin-2 therapy in patients with HIV infection publication-title: N Engl J Med doi: 10.1056/NEJMoa0903175 – reference: 17919105 - AIDS Res Hum Retroviruses. 2007 Sep;23(9):1105-13 – reference: 18615598 - Cytometry A. 2008 Sep;73(9):847-56 – reference: 9712056 - J Immunol. 1998 Aug 15;161(4):1875-82 – reference: 17920731 - Vaccine. 2007 Nov 7;25(45):7737-42 – reference: 18842730 - J Virol. 2008 Dec;82(24):12449-63 – reference: 11039923 - Science. 2000 Oct 20;290(5491):486-92 – reference: 9933172 - Science. 1999 Feb 5;283(5403):857-60 – reference: 8805770 - Biometrics. 1996 Sep;52(3):1103-11 – reference: 9367954 - Science. 1997 Nov 21;278(5342):1447-50 – reference: 16959262 - J Immunol Methods. 2006 Aug 31;315(1-2):121-32 – reference: 17391815 - Vaccine. 2007 May 16;25(20):4085-92 – reference: 15297060 - Vaccine. 2004 Aug 13;22(23-24):3092-7 – reference: 9562581 - N Engl J Med. 1998 Apr 30;338(18):1272-8 – reference: 19828532 - N Engl J Med. 2009 Oct 15;361(16):1548-59 – reference: 17325604 - J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):601-5 – reference: 9234539 - Vaccine. 1997 Jun;15(8):884-7 – reference: 17106277 - J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12 – reference: 8483929 - Proc Natl Acad Sci U S A. 1993 May 1;90(9):4156-60 – reference: 17109336 - J Infect Dis. 2006 Dec 15;194(12):1650-60 – reference: 17039602 - Virology. 2006 Sep 30;353(2):268-82 – reference: 16890329 - Vaccine. 2006 Nov 17;24(47-48):6893-904 – reference: 10075982 - J Exp Med. 1999 Mar 15;189(6):991-8 – reference: 17451739 - J Immunol Methods. 2007 May 31;323(1):39-54 – reference: 8857018 - N Engl J Med. 1996 Oct 31;335(18):1350-6 – reference: 19012957 - Lancet. 2008 Nov 29;372(9653):1894-905 – reference: 9345075 - N Engl J Med. 1997 Oct 30;337(18):1267-74 – reference: 17709802 - Ann Oncol. 2007 Oct;18(10):1691-7 – reference: 17109335 - J Infect Dis. 2006 Dec 15;194(12):1638-49 – reference: 19843557 - N Engl J Med. 2009 Dec 3;361(23):2209-20 – reference: 9516219 - N Engl J Med. 1998 Mar 26;338(13):853-60 – reference: 9144471 - J Immunol. 1997 May 15;158(10):4591-601 – reference: 9516110 - Science. 1998 Mar 27;279(5359):2103-6 – reference: 19012954 - Lancet. 2008 Nov 29;372(9653):1881-93 – reference: 20549207 - Cancer Immunol Immunother. 2010 Oct;59(10):1489-501 – reference: 17310936 - J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7 – reference: 9632379 - Science. 1998 Jun 19;280(5371):1875-80 – reference: 10759543 - Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4192-7 – reference: 17049679 - Vaccine. 2007 Jan 5;25(3):510-8 – reference: 17457219 - J Immunother. 2007 May-Jun;30(4):448-54 – reference: 20173752 - Nat Med. 2010 Mar;16(3):319-23 |
| SSID | ssj0004367 |
| Score | 2.1604497 |
| Snippet | Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we... Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we... To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a... Background. To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we... |
| SourceID | unpaywall pubmedcentral proquest pubmed pascalfrancis crossref oup jstor |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1541 |
| SubjectTerms | Adjuvants, Immunologic - administration & dosage Adolescent Adult AIDS Vaccines - administration & dosage AIDS Vaccines - adverse effects AIDS Vaccines - immunology Antibodies Antibodies, Viral - analysis Applied microbiology Biological and medical sciences Cytokines DNA DNA vaccines Double-Blind Method Enzyme-Linked Immunosorbent Assay Enzyme-Linked Immunospot Assay Female Fundamental and applied biological sciences. Psychology Health care administration HIV HIV 1 HIV Seronegativity - immunology HIV-1 - immunology HIV/AIDS Human immunodeficiency virus 1 Human immunodeficiency virus 2 Humans Infectious diseases Interleukin-2 - administration & dosage Interleukin-2 - immunology Major and Brief Reports Male Medical sciences Microbiology Miscellaneous Plasmids Plasmids - administration & dosage T lymphocytes T-Lymphocytes - immunology T-Lymphocytes - metabolism Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, DNA - administration & dosage Vaccines, DNA - adverse effects Vaccines, DNA - immunology Viral Envelope Proteins - analysis Virology Young Adult |
| Title | Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects |
| URI | https://www.jstor.org/stable/41329805 https://www.ncbi.nlm.nih.gov/pubmed/21940420 https://www.proquest.com/docview/1654685137 https://www.proquest.com/docview/905667808 https://pubmed.ncbi.nlm.nih.gov/PMC3222108 https://academic.oup.com/jid/article-pdf/204/10/1541/18065397/jir615.pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 204 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 1537-6613 databaseCode: KQ8 dateStart: 19970401 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 20241102 omitProxy: true ssIdentifier: ssj0004367 issn: 1537-6613 databaseCode: DIK dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 1537-6613 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED9tnWBIiI_BIHxURkJ8SLhNGjtxHquJ0SI27WGdylNkO0lXVtJqTYTKX885TgoFBjwg5c0XR7HPdz_7fL8DeC4Vwg4WMcpdT1GW8h5VaZhSjyd-oKSvODfJyUfHwWDE3o_5eAsGTS6MrG-Fd5qUhk84J_Ug0kWS4Wad4Urvouf3up6omFVDFLpEz9zB9m3YCTii8hbsjI5P-h8bsnBPVKUkcX2HFF2SX9Nt4n6-izOZTJd1Hxvuyd5QbFLfbi7kEsctswUvfodIf71YuVvmC7n6ImezH7zW4W2YNv9rL6tcdMpCdfTXn6gg_8eA3IFbNbQlffvWXdhK8z24Zotdrvbg-lEdxr8H5ampJTYh84ycIHr_PE3IwaqYX2AjeTX8QHvd4eQ12eT1JX1784QMhmfUI2dSm77I0OS3zHEVYNfFikzzqh0t4DxPJxWpOUHbaA6blvdhdPj29GBA6_oPVHOXFTTjiaGrd3mSCpEFPoKnIJKoVJmSQqYZ14InEvdULioi7nSzQMvQ5SJJfAQhgfT3oZXj1x4CQSvlKRa6WSgV01pFOsCNMwuFFIzpXuDAm2baY12To5saHbPYBun92GpJbAfWgRdr8YVlBblKcL_SobUUYoZeJFxseIYT-reX2xsqt5buMRP9ZAw7aXQwRqtgQj0yT-flMq5y1BBM-6ED5AqZCLEvQhVXOPDAqu33D3gRQ2vuOhBuKPRawJCSb7bk0_OKnNxE7jzT58u16v_5Lx_9s-RjuFGd6JuHP4FWcVmmTxESFqoN2-_GXrte898AIPpgKQ |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Zb9QwEB6VrTgkxFEohKMyEuKQ8G6ysRPncVVR7SJa9aFblafIzrGELsmqmwgtv55xnAQCFHhAypsnjmKPZz57PN8APJcKYQcLGOW2oyhL-JiqxE-ow2PXU9JVnOvk5MMjbzpn78742RZM21wY2dwKH7YpDZ9wTppBpKs4xc06w5U-Qs_vjBxRM6v6KHSBnnmI7Vdg2-OIygewPT86nnxoycIdUZeSxPXtU3RJbkO3ifv5Ec5knK2bPnruydxQbFPfbq7kGsctNQUvfodIf71Yeb3KV3LzRS6XP3itg9uQtf9rLqucD6tSDaOvP1FB_o8BuQO3GmhLJuatu7CV5Dtw1RS73OzAtcMmjH8PqhNdS2xBipQcI3r_nMVkf1MW59hIXs3e0_FotnhN-ry-ZGJunpDp7JQ65FRGui8y0_ktBa4C7LrckCyv29ECFnmyqEnNCdpGfdi0vg_zg7cn-1Pa1H-gEbdZSVMea7p6m8eJEKnnInjyAolKlSopZJLySPBY4p7KRkXEnW7qRdK3uYhjF0GIJ91dGOT4tYdA0Eo5ivl26kvFokgFkYcbZ-YLKRiLxp4Fb9ppD6OGHF3X6FiGJkjvhkZLQjOwFrzoxFeGFeQywd1ahzopxAzjQNjY8Awn9G8v7_VUrpMeMx39ZAw7aXUwRKugQz0yT4pqHdY5agimXd8CcolMgNgXoYotLHhg1Pb7B5yAoTW3LfB7Ct0JaFLyfkuefazJyXXkztF9vuxU_89_-eifJR_DjfpEXz_8CQzKiyp5ipCwVHvNav8G5Z9fOA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Timing+of+Plasmid+Cytokine+%28IL-2%2FIg%29+Administration+Affects+HIV-1+Vaccine+Immunogenicity+in+HIV-Seronegative+Subjects&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Baden%2C+Lindsey+R.&rft.au=Blattner%2C+William+A.&rft.au=Morgan%2C+Cecilia&rft.au=Huang%2C+Yunda&rft.date=2011-11-15&rft.pub=Oxford+University+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=204&rft.issue=10&rft.spage=1541&rft.epage=1549&rft_id=info:doi/10.1093%2Finfdis%2Fjir615&rft.externalDocID=10.1093%2Finfdis%2Fjir615 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |